Rite Aid has selected long-time company executive Matt Schroeder as the company's new chief ... [+] executive officer as the company exits federal bankruptcy protection, the company said September 3, 2024. Rite Aid Rite Aid has selected long-time company executive Matt Schroeder as the company's new chief executive officer as the company exits federal bankruptcy protection. Rite Aid, which has eliminated $2 billion of total debt and "received approximately $2.5 billion in exit financing to support the busin ...

The drugstore chain on Monday filed a "notice of additional closing stores" with the US Bankruptcy Court of the District of New Jersey, identifying a total of 27 locations in Michigan and Ohio that it has added to the chopping block. FOX Business reached out to Rite Aid for comment regarding the additional planned closures but did not receive a response by the time of publication. It has been undergoing bankruptcy proceedings since mid-October, when it announced its decision to pursue Chapter 11 as part of ...

Financial Data and Key Metrics Changes - Adjusted EBITDA for Q1 2024 was $91.7 million, down from $100.1 million in Q1 2023, reflecting a decrease in performance [17][18] - The company reported a net loss of $306.7 million or $5.56 per share, with an adjusted net loss of $40.1 million or $0.73 per share [17] - The medical loss ratio at Elixir Insurance is expected to trend higher than initially forecasted, impacting adjusted EBITDA for fiscal 2024 [17][18] Business Line Data and Key Metrics Changes - Retail Pharmacy segment revenues increased by 3.4% year-over-year, driven by acute and maintenance prescriptions, but offset by reduced COVID-related revenue and front-end sales [18] - Same-store sales increased by 8.4%, with pharmacy sales up 13.3% and front-end sales down 4.4% [18][19] - Elixir's revenues decreased by 30% year-over-year to $1.2 billion, with adjusted EBITDA dropping to $21.7 million from $26.4 million [20] Market Data and Key Metrics Changes - The company experienced a 4.7% increase in same-store prescriptions adjusted to 30 days, or 7.4% excluding COVID impacts [19] - Front-end sales on a comp store basis were down 7.9%, attributed to reduced demand for respiratory products and supply chain challenges [12][19] Company Strategy and Development Direction - The company is focused on a turnaround strategy that includes controlling SG&A expenses, growing scripts, and reducing drug purchasing costs [7][8] - Plans to exit the individual Medicare Part D market effective January 2024 due to unfavorable changes in utilization and drug mix [15][17] - The company aims to improve front-end sales through initiatives like enhancing product assortment and pricing strategies [34][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds such as soft front-end sales and higher medical loss ratios but emphasized strong script growth and cost control initiatives [7][8] - The company expects front-end sales trends to improve in subsequent quarters, although overall sales for the year may be lower than initially planned [25] - Management remains optimistic about the potential for growth in the pharmacy business and is focused on long-term success [8][16] Other Important Information - The company ended the fiscal quarter with approximately $1.15 billion in liquidity, with a noted increase in leverage ratio [22] - The company is evaluating options for addressing 2025 debt maturities but did not provide specific updates [23] Q&A Session Summary Question: Impact of COVID vaccines and tests in the quarter - The company administered about 1.7 million COVID vaccines last year, dropping to less than 500,000 this year, and dispensed about 2.5 million antigen kits, lower than last year's Q1 [29][31] Question: Financial benefits of adherence programs - Strong script growth of 7.4% without COVID impacts is driven by adherence initiatives, with expectations for continued improvement throughout the year [33] Question: Impact of exiting the individual Part D market - The company serves about 300,000 lives in the Med D plan, which are expected to be lost as of January 1, 2024, and these lives are not profitable [35] Question: Debt securities and capital structure discussions - The company is in open dialogue with lenders and evaluating several pathways to address capital structure, focusing on long-term growth [38] Question: Shrink issues and new leadership - The company faced a $9 million increase in shrink compared to last year, and new leadership is expected to bring innovative solutions to address this ongoing issue [49][50] Question: Stabilization in generic pricing - The company is seeing stabilization in generic pricing and is maximizing flexibility in purchasing arrangements to capture savings [51]